Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978205513> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2978205513 endingPage "S533" @default.
- W2978205513 startingPage "S533" @default.
- W2978205513 abstract "Introduction: Opioid-induced constipation (OIC) frequently results from chronic opioid treatment. Lubiprostone (LUB) efficacy was evaluated in 3 similar phase 3, randomized, double-blind, placebocontrolled, 12-week studies in chronic, non-cancer pain patients with OIC (<3 spontaneous bowel movements [SBMs]/week) at baseline. Two studies enrolled methadone users: 1 met the primary endpoint of change from baseline (CFB) in SBM frequency at Week 8, the other did not. Despite similar design, mean morphine equivalent daily dose (MEDD) of methadone in LUB-treated subjects in the latter study was 32% higher than in the successful study. Unknown at the time of these studies, methadone dosedependently inhibits the ClC-2-mediated secretory effect of LUB (Cuppoletti et al., Cell Biochem Biophys 2013;66:53-63). Methods: Post-hoc sensitivity analyses were used to evaluate the impact of high-dose methadone on CFB in SBM frequency at Week 8 in the intent-to-treat (ITT) population excluding all subjects taking methadone, and separately, excluding subjects taking high-dose (≥200 mg MEDD) methadone. A final sensitivity analysis used a median group replacement simulation for this endpoint. In this analysis, group median values for non-methadone patients and patients taking <200 mg MEDD methadone replaced Week 8 CFB values of methadone and high-dose methadone patients, respectively. Results: Excluding methadone-treated subjects from analysis resulted in clearly improved observed treatment effects in favor of LUB in both studies (Table). Though the second study did not achieve statistical significance in this analysis, clinical effect size was similar across the studies and thus the results were corroborative. In the replacement simulation, highly statistically and clinically significant improvements were observed for both trials for all simulations (p≤0.001). Adverse events were generally mild to moderate, and primarily gastrointestinal. Conclusion: LUB appears effective and well-tolerated in OIC patients with chronic, non-cancer pain taking non-methadone-type opioids. Disclosure - Ms. Losch-Beridon - Employee and holder of stock options: Sucampo Pharma Americas, LLC; Dr. Lichtlen - Consultant to Sucampo; Mr. Wang - Employee of Sucampo Pharma Americas, LLC. This research was supported by an industry grant from Sucampo Pharma Americas, LLC; Takeda Pharmaceuticals International, Inc.Table 1: Methadone Sensitivity Analyses: Change From Baseline, SBM Frequency, Week 8" @default.
- W2978205513 created "2019-10-10" @default.
- W2978205513 creator A5028533210 @default.
- W2978205513 creator A5030074432 @default.
- W2978205513 creator A5082417051 @default.
- W2978205513 date "2014-10-01" @default.
- W2978205513 modified "2023-09-25" @default.
- W2978205513 title "Lubiprostone for Treatment of Opioid-induced Constipation: Analysis of Influencing Factors" @default.
- W2978205513 doi "https://doi.org/10.14309/00000434-201410002-01801" @default.
- W2978205513 hasPublicationYear "2014" @default.
- W2978205513 type Work @default.
- W2978205513 sameAs 2978205513 @default.
- W2978205513 citedByCount "0" @default.
- W2978205513 crossrefType "journal-article" @default.
- W2978205513 hasAuthorship W2978205513A5028533210 @default.
- W2978205513 hasAuthorship W2978205513A5030074432 @default.
- W2978205513 hasAuthorship W2978205513A5082417051 @default.
- W2978205513 hasConcept C126322002 @default.
- W2978205513 hasConcept C168563851 @default.
- W2978205513 hasConcept C170493617 @default.
- W2978205513 hasConcept C203092338 @default.
- W2978205513 hasConcept C2778767360 @default.
- W2978205513 hasConcept C2778903061 @default.
- W2978205513 hasConcept C2781063702 @default.
- W2978205513 hasConcept C2781093762 @default.
- W2978205513 hasConcept C2781112942 @default.
- W2978205513 hasConcept C2908647359 @default.
- W2978205513 hasConcept C3017955636 @default.
- W2978205513 hasConcept C42219234 @default.
- W2978205513 hasConcept C67761136 @default.
- W2978205513 hasConcept C71924100 @default.
- W2978205513 hasConcept C99454951 @default.
- W2978205513 hasConceptScore W2978205513C126322002 @default.
- W2978205513 hasConceptScore W2978205513C168563851 @default.
- W2978205513 hasConceptScore W2978205513C170493617 @default.
- W2978205513 hasConceptScore W2978205513C203092338 @default.
- W2978205513 hasConceptScore W2978205513C2778767360 @default.
- W2978205513 hasConceptScore W2978205513C2778903061 @default.
- W2978205513 hasConceptScore W2978205513C2781063702 @default.
- W2978205513 hasConceptScore W2978205513C2781093762 @default.
- W2978205513 hasConceptScore W2978205513C2781112942 @default.
- W2978205513 hasConceptScore W2978205513C2908647359 @default.
- W2978205513 hasConceptScore W2978205513C3017955636 @default.
- W2978205513 hasConceptScore W2978205513C42219234 @default.
- W2978205513 hasConceptScore W2978205513C67761136 @default.
- W2978205513 hasConceptScore W2978205513C71924100 @default.
- W2978205513 hasConceptScore W2978205513C99454951 @default.
- W2978205513 hasLocation W29782055131 @default.
- W2978205513 hasOpenAccess W2978205513 @default.
- W2978205513 hasPrimaryLocation W29782055131 @default.
- W2978205513 hasRelatedWork W1873423066 @default.
- W2978205513 hasRelatedWork W2031548893 @default.
- W2978205513 hasRelatedWork W2052473931 @default.
- W2978205513 hasRelatedWork W2061419434 @default.
- W2978205513 hasRelatedWork W2154946233 @default.
- W2978205513 hasRelatedWork W2324982409 @default.
- W2978205513 hasRelatedWork W2373693166 @default.
- W2978205513 hasRelatedWork W2734740211 @default.
- W2978205513 hasRelatedWork W2962868152 @default.
- W2978205513 hasRelatedWork W4232758905 @default.
- W2978205513 hasVolume "109" @default.
- W2978205513 isParatext "false" @default.
- W2978205513 isRetracted "false" @default.
- W2978205513 magId "2978205513" @default.
- W2978205513 workType "article" @default.